SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. SvenssonView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. PeloquinView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. SvenssonView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. SchipaniView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016High drug tolerance of Mycobacterium tuberculosis in caseum | J. SarathyView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. BlumbergView Slideset
AOAndrew OwenBSS, MSC, PhD, FSBSlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. RajoliView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. WichaView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. DooleyView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. HatleyView Slideset
